Related Experiment Videos
Community-acquired pneumonia: an approach to antimicrobial therapy
1Division of Infectious Diseases, St. Luke's-Roosevelt Hospital, New York, New York, USA.
Abstract:
Community-acquired pneumonia (CAP), the sixth leading cause of death in the United States, has undergone significant changes in the past 30 years. In addition to the fact that it increasingly is a disease affecting the elderly and those patients with underlying comorbidities, the spectrum of microbiological agents causing pneumonia has greatly expanded and includes in addition to Streptococcus pneumoniae many other agents including Mycoplasma, Chlamydia, and respiratory viruses. A major problem encountered by the clinician facing a patient with CAP derives from the imprecise clinical presentation, which in most instances does not permit a precise diagnosis of the etiological agent. As pneumonia, if untreated, is frequently a rapidly progressive illness, the clinician usually chooses antimicrobial agents on an empirical basis. Careful attention to historical, physical, and laboratory findings, as well as age and presence of comorbidities has led to a categorization of CAP into four groupings that assist in deciding whether the patient should be hospitalized and what empirical antimicrobial regimen should be started. Careful follow-up and familiarity with the clinical pneumonic syndromes associated with different microbial agents is essential to assure a successful outcome.
Insights
Community-acquired pneumonia (CAP) is a growing concern, especially in the elderly and those with comorbidities. Diagnosis is challenging due to varied causes and imprecise symptoms, necessitating empirical treatment.
Area of Science:
- Medicine
- Infectious Diseases
- Pulmonology
Background:
- Community-acquired pneumonia (CAP) is a significant cause of mortality in the US.
- CAP increasingly affects the elderly and individuals with comorbidities.
- The etiological spectrum of CAP has broadened beyond Streptococcus pneumoniae to include Mycoplasma, Chlamydia, and viruses.
Purpose of the Study:
- To address the challenges in diagnosing CAP due to imprecise clinical presentations.
- To guide empirical antimicrobial therapy selection for CAP patients.
- To improve patient outcomes through careful management and follow-up.
Main Methods:
- Categorization of CAP into four groupings based on clinical, historical, and laboratory findings.
- Consideration of patient age and comorbidities in treatment decisions.
- Empirical antimicrobial agent selection based on clinical presentation and risk factors.
Main Results:
- Clinical presentation often lacks precision for etiological diagnosis.
- Empirical treatment is frequently necessary due to the rapid progression of pneumonia.
- A four-group categorization aids in hospitalization decisions and empirical regimen selection.
Conclusions:
- Accurate diagnosis of the etiological agent in CAP is often difficult.
- Empirical antimicrobial therapy is a common and necessary approach.
- Effective management of CAP requires careful patient assessment, risk stratification, and tailored treatment strategies.